Sugi Predict

Sugi Predict / Compounds / SCHEMBL720570

SCHEMBL720570

SCHEMBL720570

Cc1nn(-c2cccc(Cl)c2)cc1C(Nc1ccc(C(=O)N(C)CCC(=O)O)cc1)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GCG P01275 8/20 0.44
▸ RCE1 Q9Y256 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ GLP1R P43220 1/20 0.35
▸ GCGR P47871 1/20 0.35
▸ GIPR P48546 1/20 0.35
▸ SLC6A7 Q99884 1/20 0.34
▸ P2RX7 Q99572 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ HSD11B1 P28845 1/20 0.34
▸ HSD11B2 P80365 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ GPR142 Q7Z601 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719899 0.92 GCG (0.45) GCGRCE1MEN1KMT2AGLP1R
SCHEMBL718414 0.92 GCG (0.43) GCGRCE1GLP1RGCGRGIPR
SCHEMBL721260 0.92 CASP3 (0.38) GCGRCE1ALDH1A1HSD11B1HSD11B2
SCHEMBL720391 0.91 GCG (0.40) GCGRCE1MEN1KMT2AGCGR
SCHEMBL718417 0.88 GCG (0.36) GCGRCE1MEN1POLBKMT2A
SCHEMBL717929 0.88 GCG (0.46) GCGRCE1MEN1POLBKMT2A
SCHEMBL720562 0.88 GCG (0.41) GCGRCE1GLP1RGCGRGIPR
SCHEMBL717855 0.86 SLC6A9 (0.42) GCGMEN1KMT2AGLP1RGCGR
SCHEMBL721092 0.85 GCGR (0.51) GCGGLP1RGCGRGIPR
SCHEMBL717775 0.84 MAPT (0.39) GCGMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 — — US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 — — US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 — — US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 — — US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 — — US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 — — US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 — — US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 — — EP disclosed
WO-2009110520-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP GCG 35/4885RCE1 2661/4885MEN1 444/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP GCG 35/4885RCE1 2661/4885MEN1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.